Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study.
Kenneth R ChapmanKathryn CoggerErin ArthursCallahan LaFortyShane GoldenBradley MillsonKoyo UsubaChristopher LicskaiPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2024)
In a real-world population of Canadian patients with severe asthma with an eosinophilic phenotype, the use of mepolizumab within a patient support program reduced asthma exacerbations and decreased asthma-related healthcare resource utilization and associated costs.